Quince Therapeutics, Inc.
QNCX
$1.61
$0.010.63%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 168.44% | -50.85% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 69.98% | -10.96% | |||
| Operating Income | -69.98% | 10.96% | |||
| Income Before Tax | -20.34% | -127.25% | |||
| Income Tax Expenses | 571.43% | -46.15% | |||
| Earnings from Continuing Operations | -20.65% | -126.84% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -20.65% | -126.84% | |||
| EBIT | -69.98% | 10.96% | |||
| EBITDA | -69.92% | 10.25% | |||
| EPS Basic | -20.17% | -123.74% | |||
| Normalized Basic EPS | -65.50% | 2.95% | |||
| EPS Diluted | -20.17% | -123.74% | |||
| Normalized Diluted EPS | -65.50% | 2.95% | |||
| Average Basic Shares Outstanding | 0.37% | 1.42% | |||
| Average Diluted Shares Outstanding | 0.37% | 1.42% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||